---
document_datetime: 2025-12-29 11:14:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kyprolis.html
document_name: kyprolis.html
version: success
processing_time: 0.1226106
conversion_datetime: 2025-12-30 02:27:55.735492
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kyprolis

[RSS](/en/individual-human-medicine.xml/65885)

##### Authorised

This medicine is authorised for use in the European Union

carfilzomib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kyprolis](#news-on)
- [Related content](#related-content-552)
- [More information on Kyprolis](#more-information-on-kyprolis-81428)
- [More information on Kyprolis](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kyprolis is a cancer medicine used together with the medicines daratumumab and dexamethasone, or lenalidomide and dexamethasone or with dexamethasone alone, to treat multiple myeloma (a cancer of the bone marrow). It is given to adults who have received at least one previous treatment for their cancer.

Kyprolis contains the active substance carfilzomib.

Multiple myeloma is rare, and Kyprolis was designated an 'orphan medicine' (a medicine used in rare diseases) on 3 June 2008.

Expand section

Collapse section

## How is Kyprolis used?

Kyprolis can only be obtained with a prescription and treatment must be supervised by a doctor experienced in the treatment of cancer.

Kyprolis is given by infusion (drip) into a vein over 10 to 30 minutes. The dose is calculated using the patient's height and weight. It is given on two days of the first 3 weeks of 4-week treatment cycles. After a year, doses in the second week are omitted if the combination of Kyprolis and dexamethasone is used with either lenalidomide or daratumumab. Treatment should continue for as long as the patient benefits from it. Treatment may need to be stopped or the dose reduced if the disease gets worse or the patient has severe side effects.

For more information about using Kyprolis, see the package leaflet or contact your doctor or pharmacist.

## How does Kyprolis work?

The active substance in Kyprolis, carfilzomib, is a proteasome inhibitor. This means that it blocks the proteasome, which is a system within the cells that breaks down proteins that are no longer needed. Cancer cells have an increased need to produce and break down proteins because they multiply rapidly. When carfilzomib stops the proteasome from breaking down proteins in the cancer cells, the proteins build up and cause the cells to die, slowing down the growth of the cancer.

## What benefits of Kyprolis have been shown in studies?

Kyprolis taken together with lenalidomide and dexamethasone has been compared with lenalidomide plus dexamethasone in one main study involving 792 patients with multiple myeloma whose disease had got worse after previous treatment. The study showed that Kyprolis is effective at prolonging the time patients lived without their disease getting worse (progression-free survival): patients receiving Kyprolis with lenalidomide and dexamethasone lived on average for 26.3 months without their disease getting worse, compared with 17.6 months for patients receiving lenalidomide plus dexamethasone.

Another study in 929 multiple myeloma patients whose disease had got worse after previous treatment compared the combination of Kyprolis and dexamethasone with bortezomib and dexamethasone. The study showed that the combination of Kyprolis and dexamethasone is more effective at improving progression-free survival than bortezomib and dexamethasone: patients receiving Kyprolis plus dexamethasone lived for an average of 18.7 months without their disease getting worse, compared with 9.4 months for patients receiving bortezomib and dexamethasone.

A third study involved 466 patients with multiple myeloma whose disease had got worse after previous treatment. It found that 35% of patients treated with Kyprolis plus daratumumab and dexamethasone had worsening of the disease or died compared with 44% of patients treated with Kyprolis plus dexamethasone.

## What are the risks associated with Kyprolis?

The most common side effects with Kyprolis (which may affect more than 1 in 5 people) are anaemia (low red blood cell counts), tiredness, nausea, diarrhoea, thrombocytopenia (low blood platelet counts), fever, dyspnoea (difficulty breathing), respiratory tract (airways) infection, cough and neutropenia (low levels of neutrophils, a type of white blood cell).

The most serious side effects when used with lenalidomide and dexamethasone or with dexamethasone alone include harmful effects on the heart, lungs and liver, and hypertension (high blood pressure) that can be severe. Other serious side effects are dyspnoea, acute kidney injury, tumour lysis syndrome (a complication due to the breakdown of cancer cells), infusion-related reactions, thrombocytopenia, internal bleeding, liver damage, return of symptoms of hepatitis B, posterior reversible encephalopathy syndrome (a brain disorder that can cause headache, confusion, fits and loss of vision, and which may improve over time) as well as thrombotic microangiopathy and TTP/HUS (diseases involving problems with the blood clotting system). The most serious side effects when used with daratumumab and dexamethasone were anaemia, diarrhoea, fever, pneumonia (infection of the lungs), influenza (flu), sepsis (blood poisoning) and bronchitis (inflammation of the airways in the lungs).

Kyprolis must not be used in women who are breastfeeding. For the full list of side effects and restrictions, see the package leaflet.

## Why is Kyprolis authorised in the EU?

The European Medicines Agency decided that Kyprolis' benefits are greater than its risks and it can be authorised for use in the EU. The Agency noted the unmet medical need for patients with multiple myeloma who no longer improve with the available therapies. It considered that the increase in time patients lived without the disease getting worse with Kyprolis was clinically meaningful. Regarding safety, although side effects, including severe effects, were seen with treatment involving Kyprolis, these were considered acceptable and manageable.

## What measures are being taken to ensure the safe and effective use of Kyprolis?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kyprolis have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kyprolis are continuously monitored. Side effects reported with Kyprolis are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kyprolis

Kyprolis received a marketing authorisation valid throughout the EU on 19 November 2015.

Kyprolis : EPAR - Medicine overview

Reference Number: EMA/629102/2020

English (EN) (130.53 KB - PDF)

**First published:** 01/12/2015

**Last updated:** 28/01/2021

[View](/en/documents/overview/kyprolis-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-38)

български (BG) (142.45 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/bg/documents/overview/kyprolis-epar-medicine-overview_bg.pdf)

español (ES) (128.78 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/es/documents/overview/kyprolis-epar-medicine-overview_es.pdf)

čeština (CS) (153.53 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/cs/documents/overview/kyprolis-epar-medicine-overview_cs.pdf)

dansk (DA) (127.16 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/da/documents/overview/kyprolis-epar-medicine-overview_da.pdf)

Deutsch (DE) (131.71 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/de/documents/overview/kyprolis-epar-medicine-overview_de.pdf)

eesti keel (ET) (115.98 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/et/documents/overview/kyprolis-epar-medicine-overview_et.pdf)

ελληνικά (EL) (154.08 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/el/documents/overview/kyprolis-epar-medicine-overview_el.pdf)

français (FR) (130.29 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/fr/documents/overview/kyprolis-epar-medicine-overview_fr.pdf)

hrvatski (HR) (151.05 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/hr/documents/overview/kyprolis-epar-medicine-overview_hr.pdf)

italiano (IT) (127.4 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/it/documents/overview/kyprolis-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (160.54 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/lv/documents/overview/kyprolis-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (150.74 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/lt/documents/overview/kyprolis-epar-medicine-overview_lt.pdf)

magyar (HU) (151.72 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/hu/documents/overview/kyprolis-epar-medicine-overview_hu.pdf)

Malti (MT) (162.46 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/mt/documents/overview/kyprolis-epar-medicine-overview_mt.pdf)

Nederlands (NL) (127.15 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/nl/documents/overview/kyprolis-epar-medicine-overview_nl.pdf)

polski (PL) (152.74 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/pl/documents/overview/kyprolis-epar-medicine-overview_pl.pdf)

português (PT) (129.45 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/pt/documents/overview/kyprolis-epar-medicine-overview_pt.pdf)

română (RO) (149.96 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/ro/documents/overview/kyprolis-epar-medicine-overview_ro.pdf)

slovenčina (SK) (151.49 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/sk/documents/overview/kyprolis-epar-medicine-overview_sk.pdf)

slovenščina (SL) (149.36 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/sl/documents/overview/kyprolis-epar-medicine-overview_sl.pdf)

Suomi (FI) (126 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/fi/documents/overview/kyprolis-epar-medicine-overview_fi.pdf)

svenska (SV) (126.52 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

28/01/2021

[View](/sv/documents/overview/kyprolis-epar-medicine-overview_sv.pdf)

Kyprolis : EPAR - Risk-management-plan summary

English (EN) (89.77 KB - PDF)

**First published:** 05/06/2019

[View](/en/documents/rmp-summary/kyprolis-epar-risk-management-plan-summary_en.pdf-0)

## Product information

Kyprolis : EPAR - Product Information

English (EN) (866.29 KB - PDF)

**First published:** 01/12/2015

**Last updated:** 10/04/2024

[View](/en/documents/product-information/kyprolis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-735)

български (BG) (863.9 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/bg/documents/product-information/kyprolis-epar-product-information_bg.pdf)

español (ES) (819.6 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/es/documents/product-information/kyprolis-epar-product-information_es.pdf)

čeština (CS) (846.13 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/cs/documents/product-information/kyprolis-epar-product-information_cs.pdf)

dansk (DA) (815.16 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/da/documents/product-information/kyprolis-epar-product-information_da.pdf)

Deutsch (DE) (843.7 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/de/documents/product-information/kyprolis-epar-product-information_de.pdf)

eesti keel (ET) (804.18 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/et/documents/product-information/kyprolis-epar-product-information_et.pdf)

ελληνικά (EL) (878.63 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/el/documents/product-information/kyprolis-epar-product-information_el.pdf)

français (FR) (870.83 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/fr/documents/product-information/kyprolis-epar-product-information_fr.pdf)

hrvatski (HR) (837.95 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/hr/documents/product-information/kyprolis-epar-product-information_hr.pdf)

íslenska (IS) (798.52 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/is/documents/product-information/kyprolis-epar-product-information_is.pdf)

italiano (IT) (819.36 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/it/documents/product-information/kyprolis-epar-product-information_it.pdf)

latviešu valoda (LV) (832.84 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/lv/documents/product-information/kyprolis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (843.49 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/lt/documents/product-information/kyprolis-epar-product-information_lt.pdf)

magyar (HU) (877.41 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/hu/documents/product-information/kyprolis-epar-product-information_hu.pdf)

Malti (MT) (888.55 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/mt/documents/product-information/kyprolis-epar-product-information_mt.pdf)

Nederlands (NL) (818.09 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/nl/documents/product-information/kyprolis-epar-product-information_nl.pdf)

norsk (NO) (842.32 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/no/documents/product-information/kyprolis-epar-product-information_no.pdf)

polski (PL) (871.47 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/pl/documents/product-information/kyprolis-epar-product-information_pl.pdf)

português (PT) (813.47 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/pt/documents/product-information/kyprolis-epar-product-information_pt.pdf)

română (RO) (856.48 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/ro/documents/product-information/kyprolis-epar-product-information_ro.pdf)

slovenčina (SK) (862.27 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/sk/documents/product-information/kyprolis-epar-product-information_sk.pdf)

slovenščina (SL) (967.03 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/sl/documents/product-information/kyprolis-epar-product-information_sl.pdf)

Suomi (FI) (812.65 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/fi/documents/product-information/kyprolis-epar-product-information_fi.pdf)

svenska (SV) (804.15 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

10/04/2024

[View](/sv/documents/product-information/kyprolis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0058 14/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kyprolis : EPAR - All Authorised presentations

English (EN) (12.73 KB - PDF)

**First published:** 01/12/2015

**Last updated:** 15/09/2016

[View](/en/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-689)

български (BG) (53.34 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/bg/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_bg.pdf)

español (ES) (7.43 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/es/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (83.61 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/cs/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.05 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/da/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (10.08 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/de/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (10.05 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/et/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (78.38 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/el/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_el.pdf)

français (FR) (7.27 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/fr/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (81.5 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/hr/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (9.99 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/is/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.05 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/it/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (85.05 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/lv/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (84.52 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/lt/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (45.03 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/hu/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (87.25 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/mt/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (10.05 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/nl/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (10.07 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/no/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_no.pdf)

polski (PL) (85.24 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/pl/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_pl.pdf)

português (PT) (10.11 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/pt/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_pt.pdf)

română (RO) (83.1 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/ro/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (85.19 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/sk/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.42 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/sl/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (10 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/fi/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (10.02 KB - PDF)

**First published:**

01/12/2015

**Last updated:**

15/09/2016

[View](/sv/documents/all-authorised-presentations/kyprolis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kyprolis Active substance carfilzomib International non-proprietary name (INN) or common name carfilzomib Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01XX45

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

## Authorisation details

EMA product number EMEA/H/C/003790

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

Opinion adopted 24/09/2015 Marketing authorisation issued 19/11/2015 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kyprolis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (274.46 KB - PDF)

**First published:** 26/04/2016

**Last updated:** 10/04/2024

[View](/en/documents/procedural-steps-after/kyprolis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kyprolis-H-C-PSUSA-00010448-202007: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/107362/2021

English (EN) (160.86 KB - PDF)

**First published:** 07/05/2021

[View](/en/documents/scientific-conclusion/kyprolis-h-c-psusa-00010448-202007-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Kyprolis-H-C-3790-II-0045 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/593622/2020

English (EN) (8.19 MB - PDF)

**First published:** 28/01/2021

[View](/en/documents/variation-report/kyprolis-h-c-3790-ii-0045-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Kyprolis (II-45)

Adopted

Reference Number: EMA/CHMP/593624/2020

English (EN) (131.93 KB - PDF)

**First published:** 13/11/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kyprolis-ii-45_en.pdf)

Kyprolis-H-C-PSUSA-00010448-201901 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/573870/2019

English (EN) (71.07 KB - PDF)

**First published:** 07/01/2020

[View](/en/documents/scientific-conclusion/kyprolis-h-c-psusa-00010448-201901-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Kyprolis-H-C-PSUSA-00010448-201807 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/302553/2019

English (EN) (68.54 KB - PDF)

**First published:** 05/06/2019

[View](/en/documents/scientific-conclusion/kyprolis-h-c-psusa-00010448-201807-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Kyprolis-H-C-PSUSA-00010448-201707 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/254102/2018

English (EN) (108.61 KB - PDF)

**First published:** 24/04/2018

**Last updated:** 24/04/2018

[View](/en/documents/scientific-conclusion/kyprolis-h-c-psusa-00010448-201707-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Kyprolis-H-C-PSUSA-00010448-201707 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/818971/2017

English (EN) (107.1 KB - PDF)

**First published:** 11/12/2017

**Last updated:** 11/12/2017

[View](/en/documents/scientific-conclusion/kyprolis-h-c-psusa-00010448-201707-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Kyprolis-H-C-3790-II-0001-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/517040/2016

English (EN) (4.77 MB - PDF)

**First published:** 04/08/2016

**Last updated:** 04/08/2016

[View](/en/documents/variation-report/kyprolis-h-c-3790-ii-0001-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Kyprolis

Adopted

Reference Number: EMA/CHMP/340832/2016

English (EN) (66.71 KB - PDF)

**First published:** 27/05/2016

**Last updated:** 27/05/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kyprolis_en.pdf)

## Initial marketing authorisation documents

Kyprolis : EPAR - Public assessment report

Adopted

Reference Number: EMA/670306/2015

English (EN) (4.89 MB - PDF)

**First published:** 01/12/2015

**Last updated:** 01/12/2015

[View](/en/documents/assessment-report/kyprolis-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion Kyprolis

Adopted

Reference Number: EMA/627858/2015

English (EN) (67.1 KB - PDF)

**First published:** 25/09/2015

**Last updated:** 25/09/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-kyprolis_en.pdf)

#### News on Kyprolis

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020) 13/11/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-may-2016) 27/05/2016

[New treatment option for patients with rare blood cancer](/en/news/new-treatment-option-patients-rare-blood-cancer) 25/09/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-september-2015) 25/09/2015

#### Related content

- [Kyprolis: Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0037900000) (initial marketing authorisation)
- [Kyprolis: Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC003790II0001G) (variation II/0001/G)

#### More information on Kyprolis

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-548) on 3 June 2008. Kyprolis was withdrawn from the Community register of orphan medicinal products in November 2025 at the end of the 10-year period of market exclusivity.

#### More information on Kyprolis

- [EMEA-001806-PIP03-18 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001806-pip03-18)
- [EMEA-001806-PIP04-19-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001806-pip04-19-m02)
- [Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least one Prior Therapy (20200445) - post-authorisation study](https://catalogues.ema.europa.eu/study/50712)
- [Retrospective Analysis of Second Primary Malignancies (SPM) Data From ASPIRE and ENDEAVOR Studies (20220146) - post-authorisation study](https://catalogues.ema.europa.eu/study/104100)
- [Risk factors for cardiac events in carfilzomib-treated patients in the Marketscan database (20160186) - post-authorisation study](https://catalogues.ema.europa.eu/study/19462)
- [Postmarketing Surveillance Study for Kyprolis® (carfilzomib) in Korea (20160117) - post-authorisation study](https://catalogues.ema.europa.eu/study/46780)
- [Real-world Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy (Use of Carfilzomib In Multiple Myeloma Patients) - post-authorisation study](https://catalogues.ema.europa.eu/study/40100)
- [Risk Prediction, Prognosis and Management of Cardiac Events among Patients with Multiple Myeloma (20160220) - post-authorisation study](https://catalogues.ema.europa.eu/study/17624)
- [An Observational Study to Estimate Incidence Rates of Heart Failure Among US Racial and Ethnic Minority Patients With Multiple Myeloma Treated or Not Treated With Carfilzomib - post-authorisation study](https://catalogues.ema.europa.eu/study/38535)
- [A retrospective analysis of pre-existing and acquired major adverse cardiovascular events (MACE) in a real world cohort of multiple myeloma (MM) patients treated with proteasome inhibitors - post-authorisation study](https://catalogues.ema.europa.eu/study/35617)
- [An observational study of Cardiovascular complications of Carfilzomib treatment in clinical practice (Cardiovascular complications of carfilzomib) - post-authorisation study](https://catalogues.ema.europa.eu/study/33299)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/11/2025

## Share this page

[Back to top](#main-content)